B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

EPAS1

MOLECULAR TARGET

endothelial PAS domain protein 1

UniProt: Q99814NCBI Gene: 203416 compounds

EPAS1 (endothelial PAS domain protein 1) is targeted by 16 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting EPAS1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1cycloheximide1.614
2Emetine1.614
3Wortmannin1.614
4Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone1.393
5Strophanthidin 3 beta,5,14-Trihydroxy-19-oxo-5 beta-card-20(22)-enolide.1.393
6Topotecan1.393
7gedunin1.102
8Anisomycin0.691
9Bortezomib0.691
10Calcimycin0.691
11Digitoxigenin 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide.0.691
12Digoxigenin 3 beta,12 beta,14-Trihydroxy-5 beta-card-20(22)-enolide.0.691
13Digoxin0.691
14Lanatosides Glycosides from DIGITALIS lanata leaf. Lanatoside C has actions similar to DIGOXIN. Mixtures of lanatosides A, B, and C have also been used. (From Martindale,0.691
15Oxyphenbutazone0.691
16Tubercidin0.691

About EPAS1 as a Drug Target

EPAS1 (endothelial PAS domain protein 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 16 compounds with documented EPAS1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

EPAS1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.